Jared J. Grantham Symposium
To honor Dr. Jared Grantham in his retirement, the Kidney Institute at the University of Kansas Medical Center hosted the first Jared J. Grantham Symposium on May 7 - 9th, 2014 in Kansas City. Dr. Grantham's vision was to invite all of the Lillian Jean Kaplan award recipients to lead a forward-thinking and interactive forum to focus on future directions and innovations in polycystic kidney disease research. All twelve of the Kaplan Awardees were present at the inaugural symposium to give talks on their vision of " The Future of PKD Research." The Kidney Institute will continue to host the Grantham Symposium annually.
Jared J. Grantham Symposium – 2022
“The Future of PKD Research”
Friday, June 10, 8:30 am – 12:30 pm CST
Passcode: 265761 | Webinar ID: 845 2478 8761
8:30 – 8:35 am – Welcome
Alan Yu, MB, BChir, Director, Jared Grantham Kidney Institute and Division of Nephrology
8:35 – 8:45 am – Introductory Remarks
History of the Grantham Symposium and Presentation of Artwork
Jim Calvet, Ph.D., University Distinguished Professor, Biochemistry, Kansas PKD Center Director
8:45 – 9:30 am – Alessandra Boletta, Ph.D.
Head, Molecular Basis of Cystic Kidney Disorders Unit
Division of Genetics and Cell Biology
San Raffaele Scientific Institute, Milan, Italy
“Metabolic Reprogramming in Polycystic Kidney Disease”
Dr. Alessandra Boletta graduated in Biology from the University of Pavia, Italy. She carried out her doctoral training at the Mario Negri Institute in Bergamo, Italy, working on gene delivery to the kidney. She then went to Johns Hopkins University for her postdoctoral training. Here, she began her scientific activity on Polycystic Kidney Disease, working on heterologous expression of Polycystin-1 aimed at establishing cellular models to investigate its function.
With support from a Telethon Career Program and a Marie Curie Excellence Award, Dr. Boletta moved back to Italy to establish her lab at the San Raffaele Scientific Institute in Milan. Here, she took on the position of Director for the Division of Genetics and Cell Biology (2014-2019), and she is currently Head of the Research Unit. Over the years, her lab has developed several cellular and animal models to study the functions of the polycystins and the pathophysiology of ADPKD. Her laboratory has identified metabolic reprogramming as an important feature of the disease, offering several new options for therapy as well as novel insights into the pathogenesis of ADPKD. She currently serves on the PKD Foundation Scientific Advisory Panel. Dr. Boletta received the Lillian Jean Kaplan Award in 2022.
9:40 – 10:25 am – Albert Ong, DM, MA, FRCP
Professor of Renal Medicine and Head, Academic Nephrology
Department of Infection, Immunity and Cardiovascular Disease
University of Sheffield Medical School, United Kingdom
“Understanding Biological Variation in ADPKD: Lessons from Nature”
Dr. Albert Ong is Professor of Renal Medicine and Head of Academic Nephrology at the University of Sheffield, UK. Born in Malaysia, he was educated at the University of Oxford, completing postgraduate clinical and research training in nephrology at University College London and Oxford before taking up his present post. Work from his group has contributed to our fundamental understanding of the nature and functions of the ADPKD proteins, polycystin-1 and polycystin-2, in health and disease. Current areas of active research are in the role of cytoskeletal dysregulation in cystogenesis and the potential of small RNA molecules as disease biomarkers and therapeutic targets. Dr. Ong received the Lillian Jean Kaplan Award in 2022.
10:35 – 11:20 am – Arlene Chapman, M.D.
Professor of Medicine and Chief, Section of Nephrology
Director, Clinical Research Center, Institute for Translational Medicine
University of Chicago Medical Center
“ADPKD - Membership in the Cysterhood”
Dr. Arlene Chapman is Professor of Medicine, Chief of Nephrology, University of Chicago, and has spent the last 35 years evaluating clinical manifestations and therapeutic interventions in ADPKD. Dr. Chapman's research focuses on mechanisms of cyst formation in ADPKD, and she has been integrally involved in the development of novel imaging biomarkers for this disease. Dr. Chapman also studies personalized or precision medicine and the role that genetic background plays in predicting antihypertensive responses to blood pressure medications used to treat hypertension. Her work has covered the areas of hypertension, intracranial aneurysms, disease progression, htTKV as an imaging biomarker, metabolomic and urinary biomarkers in ADPKD and treatment strategies including vasopressin V2 receptor antagonists. Dr. Chapman received the Lillian Jean Kaplan Award in 2020.
11:20 – 11:40 – Break
11:40 – 12:25 – Roundtable Discussion on “The Future of PKD Research”
Moderated by Darren Wallace, Ph.D., Professor, Internal Medicine, Kansas PKD Center Co-Director
12:25 – 12:30 – Closing Remarks